In colorectal cancer, the combination of Fruquintinib or AB680 with anti-PD-1 therapy reduced the presence of Tregs and promoted the infiltration of CD8+ and IFN-γ–producing CD4+ T cells. The gene discussed is CD8A; the disease is colorectal cancer.